Biotechnology is one of the best platforms to meet the demand for better healthcare infrastructure for the diagnosis and treatment of COVID-19 infection and lower its sero-prevalence rate, during the Coronavirus (COVID-19) pandemic. Biotech companies are collaborating with government bodies, and are majorly focusing on research and development activities to develop a drug and vaccine to cure, and prevent this disease, respectively. For instance, in April 22, 2020, Biotechnology Industry Research Assistance Council (BIRAC), based in India, funded 16 companies for the development of COVID-19 therapeutics, vaccines, and devices.
Several companies such as Regeneron Pharmaceuticals and Incyt, CytoDyn are competing to develop new innovative technologies such as monoclonal technologies targeting SARS-CoV-2 virus. Currently, existing biotechnology technologies such as monoclonal antibodies (Mabs), Cell therapies and many more are utilized to identify different viruses to develop antibodies against COVID-19. For instance, in March 2020, Regeneron identified hundreds of virus-neutralizing antibodies to create an antibody cocktail therapy.
Few of the developments in this industry are as follows:
All these initiatives are expected to aid bring positive traction in the biotechnology industry. The reports from Coherent Market Insights considers and evaluates the impact of the COVID-19, and anticipated change on the future outlook of this industry, by taking into the account the political, economic, social, and technological parameters.
Pre-Covid-19 Vs Post Covid-19 - Market Estimates, 2020 – 2021 (US$ Bn)
Top Gainers Vs Top Losers
Principal Consultant Healthcare Research
Consultant Level 1 Healthcare Research
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.